Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT351 in Adults Living Without and With HIV
NCT07392372Phase 1Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BNT351 in human immunodeficiency virus infection (HIV) (6 cohorts), sponsored by BioNTech SE. Primary endpoints: Adverse Events at 56 days, Serious Adverse Events at 56 days and 10 more. Started Feb 2026; status: recruiting.
02
Drugs
BNT351
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07392372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392372.